Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill
Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc
Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2
RAPT Therapeutics has seen its shares fall sharply after the FDA placed a clinical hold on oral CCR4 antagonist zelnecirnon, currently in a phase 2b trial for atopic derma
Dermatology specialist LEO Pharma has built the case for its first-in-class chronic hand eczema (CHE) drug delgocitinib, saying it outperformed the only approved drug ther
The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year